The stock rose 11.22% to $84.56 on Monday.
In a presentation at the European Society for Medical Oncology meeting in Barcelona over the weekend, rival Immunomedics' (IMMU) sacituzumab govitecan showed a 29% response rate, short of the 44% response rate Seattle Genetics' competing drug showed. Shares of Immunomedics (IMMU) were falling 10.8% to $12.77.
"There is an unmet clinical need for new treatments for patients with HER2-positive metastatic colorectal cancer," said Dr. Roger Dansey, chief medical officer at Seattle Genetics. "The trial demonstrated that tucatinib has the potential to play a role in the treatment of colorectal cancer. We look forward to developing tucatinib in combination with trastuzumab and other therapies for the treatment of HER2-positive metastatic colorectal cancer."
Save 57% During Our Fall Sale. Join Jim Cramer's Action Alerts PLUS investment club to become a smarter investor. Click here to sign up and save!